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Background: NMDA receptors are ligand-gated ion channels with essential roles in glutamatergic synaptic
transmission and plasticity in the CNS. As co-receptors for glutamate and glycine, gating of the NMDA receptor/
channel pore requires agonist binding to the glycine sites, as well as to the glutamate sites, on the ligand-binding
domains of the receptor. In addition to channel gating, glycine has been found to prime NMDA receptors for
internalization upon subsequent stimulation of glutamate and glycine sites.
Results: Here we address the key issue of identifying molecular determinants in the glycine-binding subunit, GluN1,
that are essential for priming of NMDA receptors. We found that glycine treatment of wild-type NMDA receptors led to
recruitment of the adaptor protein 2 (AP-2), and subsequent internalization after activating the receptors by NMDA
plus glycine. However, with a glycine-binding mutant of GluN1 – N710R/Y711R/E712A/A714L – we found that treating
with glycine did not promote recruitment of AP-2 nor were glycine-treated receptors internalized when subsequently
activated with NMDA plus glycine. Likewise, GluN1 carrying a single point mutation – A714L – did not prime upon
glycine treatment. Importantly, both of the mutant receptors were functional, as stimulating with NMDA plus glycine
evoked inward currents.
Conclusions: Thus, we have identified a single amino acid in GluN1 that is critical for priming of NMDA receptors by
glycine. Moreover, we have demonstrated the principle that while NMDA receptor gating and priming share a
common requirement for glycine binding, the molecular constraints in GluN1 for gating are distinct from those for
priming.
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NMDA receptors (NMDARs) constitute a major subtype
of glutamate receptor and play important roles in nu-
merous physiological and pathophysiological processes
in the CNS [1]. NMDARs are unique in the glutamate
receptor family in that they require a co-agonist, glycine,
in addition to glutamate in order to gate receptor open-
ing [2]. The core of NMDARs is a heterotetrameric as-
sembly of two GluN1 and two GluN2 subunits; glycine
binds to GluN1 and glutamate to GluN2 [3]. NMDAR* Correspondence: mike.salter@utoronto.ca
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reproduction in any medium, provided the orheterotetramers assemble in the endoplasmic reticulum
and, after processing in the Golgi, mature NMDARs are
trafficked to the cell surface to synaptic, as well as to
extrasynaptic sites.
The number of cell-surface NMDARs is critically regu-
lated by endocytosis [4] which is either constitutive or reg-
ulated, i.e. induced by stimulation. Both constitutive and
regulated NMDAR endocytosis are dynamin-dependent
[5,6]. Regulated NMDAR endocytosis may be evoked ei-
ther heterologously, by stimulation of other receptors such
as group1 metabotropic glutamate receptors [7] or alpha-
7 nicotinic receptors [8], or homologously, by direct co-
agonist stimulation of the NMDARs themselves [6,9].
NMDARs can be ‘primed’ for homologous endocytosis
by selectively stimulating the receptors with glycine [10].
However, glycine stimulation alone does not induce. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors are internalized upon subsequent stimulation with
glutamate and glycine. Thus, glycine readies the recep-
tors, so they can be internalized when activated by both
co-agonists. At glutamatergic synapses the glycine trans-
porter, GLYT1 [11], normally maintains extracellular
glycine concentration at a level below that required
to induce priming. Blocking GLYT1 activity sufficiently
produces depression of NMDAR-mediated synaptic re-
sponses and limits NMDAR-dependent plasticity [12].
Thus, glycine-primed internalization may have a critical
role under conditions where endogenous glycine levels
rise such as high levels of neuronal firing or CNS dam-
age by hypoxia or trauma [13-16].
As a molecular correlate of priming, glycine stimula-
tion causes the AP-2 endocytic adaptor complex to be
recruited to NMDARs [10]. Thus, a working model is
that there are two mechanistically separable steps: priming
with AP-2 recruitment caused by glycine alone and endo-
cytosis per se caused by glutamate and glycine co-
stimulation [6]. In the present study we tested an implicit
assumption that the glycine priming process is mediated
through GluN1. We carried out our studies using wild-
type and mutant NMDARs expressed heterologously.
First, we established with wild-type receptors that glycine
primes internalization of recombinant NMDARs, fully re-
capitulating the characteristics of glycine-primed internal-
ization of native NMDARs. Subsequently, we found that
mutations in GluN1 prevented priming of NMDARs by
glycine, and we discovered that a single amino acid, A714,
is critical for glycine priming.
Results
To investigate molecular determinants for glycine-primed
internalization of NMDARs we expressed wild-type or mu-
tant GluN1/GluN2A or GluN1/GluN2B receptors in
HEK293 cells. We used four different approaches to
study priming and internalization of NMDARs: i) whole-
cell recording of NMDAR currents, ii) NMDAR surface
expression using cell ELISA, iii) fluorescence imaging of in-
ternalization of NMDARs and iv) co-immunoprecipitation
of NMDARs with the AP-2 complex.
Glycine-primed internalization of wild-type NMDARs
With wild-type NMDARs, we found that after treating
cells with glycine (100 μM; 5 min) the amplitude of
NMDAR-mediated currents – evoked by test applica-
tions of NMDA (50 μM) plus glycine (1 μM) – was
reduced significantly as compared with cells not treated
with glycine (Figure 1A and B). Twenty min after the
end of glycine application the NMDAR currents were:
53 ± 5% (p < 0.01) of baseline for GluN1/GluN2A recep-
tors and 57 ± 5% (p < 0.01) of baseline for GluN1/
GluN2B receptors. NMDAR current amplitude remainedstable at the depressed levels for up to 1 hr after glycine
treatment (not illustrated). Thus, with either wild-type
GluN1/GluN2A or wild-type GluN1/GluN2B recombin-
ant receptors glycine reliably and reproducibly primed
NMDARs currents for depression.
To investigate NMDAR cell-surface expression, we la-
beled NMDARs under non-permeabilizing conditions
using an antibody directed against an extracellular
epitope on GluN1, and measured the cell-surface
level by ELISA. We found that NMDAR cell-surface
level was stable when the cells were treated with ECS
alone (Figure 1C). Moreover, NMDAR cell-surface
level did not change for cells pre-treated with ECS and
then treated with NMDA (50 μM) plus glycine (1 μM),
i.e. concentrations equal to those of the test applica-
tion of NMDA plus glycine used in the electrophysio-
logical experiments. NMDAR cell surface level was
also unchanged by pre-treating the cells with glycine
(100 μM) and then treating with ECS. By contrast,
NMDAR cell-surface level was significantly decreased by
pre-treating the cells with glycine (100 μM) and treating
with NMDA (50 μM) plus glycine (1 μM) (Figure 1C): sur-
face GluN1/GluN2A receptor levels were reduced to
72 ± 2% (p < 0.01) of control and surface GluN1/GluN2B
receptors decreased to 68 ± 2% (p < 0.01). Thus, the level
of wild-type GluN1/GluN2A or GluN1/GluN2B receptors
on the cell surface was reduced by glycine pre-treatment
followed by NMDAR activation with NMDA plus glycine.
To visualize changes in NMDAR localization we took
advantage of the fluorochrome CypHer5E which is fluor-
escent in acidic pH, such as in endosomes, but which is
non-fluorescent at neutral or basic pH [17,18]. CypHer5E
was conjugated to α-bungarotoxin (BTX-CypHer5E), and
we engineered a 13-amino acid BTX-binding sequence
(BBS) [19-21] at the N-terminus of the GluN1 subunit.
Currents evoked through the BBS-GluN1/GluN2A or
BBS-GluN1/GluN2B receptors were indistinguishable
from those of wild-type receptors, as was glycine-primed
reduction of BBS-NMDAR currents (data not shown). At
the start of each imaging experiment, we tagged BBS-
NMDARs on the cell surface with BTX-CypHer5E at 4°C
to prevent constitutive internalization. After treatment,
the BBS-NMDARs remaining on the cell surface were
labeled with BTX-conjugated Alexa Fluor 488 (BTX-
AF488). In cells expressing BBS-GluN1/GluN2A or
BBS-GluN1/GluN2B receptors, we observed robust
Alexa Fluor 488 signal indicating expression of the
BBS-NMDARs. In cells expressing BBS-NMDARs, we
saw no CypHer5E signal above background after
treating with glycine (100 μM) or with NMDA (50 μM)
plus glycine (1 μM) (Figure 2A). By contrast, in cells
pre-treated with glycine (100 μM) followed by NMDA
(50 μM) plus glycine (1 μM) we observed bright red punc-
tate CypHer5E fluorescence (Figure 2A). CypHer5E puncta
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Figure 1 Glycine treatment primes depression of wild type recombinant NMDA receptors mediated currents. A, Representative traces
show responses to the test applications recorded from cells expressing GluN1/GluN2A that were treated with ECS (upper) or Glycine (lower).
Glycine (100 μM) was applied for 5 min, where indicated. For the expanded traces on the right, time indicates time after glycine treatment.
B, Histogram showing average normalized peak NMDA currents evoked by NMDA/glycine test applications 20 min after conditioning with glycine
(100 μM) to both GluN2A and GluN2B expressing HEK293 cells. C, NMDAR internalization (mean ± s.e.m.; percentage of total) measured by cell ELISA
assay in HEK293 cells expressing wild type recombinant NMDAR. Cultures (n = 6) were pre-treated with ECS or ECS containing glycine (100
μM) plus APV (100 μM) followed by ECS or with NMDA (50 μM) plus glycine (1μM). ** indicates p < 0.01 compared with ECS control.
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BBS-GluN1/GluN2B receptors. Some overlap of the
CypHer5E and BTX-AF488 signals was observed, due pri-
marily to signals in different planes being superimposed in
the projection images. The CypHer5E punctate signal was
lost upon intracellular alkalinization (not illustrated) indi-
cating that BBS-NMDARs that had been on the cell
surface at the start of the experiment were in an acidic
intracellular compartment at the end of the experiment.
We take these findings as evidence that glycine pre-
treatment followed by NMDAR activation with NMDA
plus glycine causes internalization of either GluN1/
GluN2A or GluN1/GluN2B receptors.
A molecular signature of glycine priming is recruitment
of the AP-2 adaptor complex to native NMDARs in hip-
pocampal neurons [10]. To determine whether glycine
stimulation recruits AP-2 to recombinant NMDARs, we
examined the association of GluN1/GluN2A or GluN1/
GluN2B receptors with the adaptin β2 subunit of en-
dogenous AP-2 in the HEK cells. In cells treated with ECS
alone, we detected a basal association of NMDARs and
AP-2 by co-immunoprecipitation of GluN1 with anantibody against adaptin β2 but not with a non-specific
IgG (Figure 2B). After stimulating with glycine (100 μM)
the amount of GluN1 that co-immunoprecipitated
with anti-adaptin β2 increased significantly with
GluN1/GluN2A or with GluN1/GluN2B receptors
(Figure 2B); there was no alteration of adaptin β2
immunoprecipitated. As D-APV was always included to-
gether with the glycine treatment we examined whether
D-APV might contribute to the enhanced association of
GluN1 and adaptin β2. However, we found that treating
with D-APV (100 μM) alone produced no significant
change in the amount of GluN1 co-immunoprecipitated
by anti-adaptin β2 (Additional file 1: Figure S1). Therefore,
glycine stimulation increased the association of recombin-
ant NMDARs with AP-2.
To determine whether the effects of glycine are
dependent upon the site occupied by glycine when it
acts as a co-agonist for NMDAR channel gating, we
tested the glycine site antagonist L689560 [22,23]. We
found that L689560 had no effect on the basal associ-
ation of GluN1 and adaptin β2 (Figure 3A). However,
application of L689560 with glycine (100 μM) prevented
A
BBS-GluN1/GluN2BBBS-GluN1/GluN2A








































































Figure 2 Glycine treatment primes internalization and recruitment of adaptin β2 to the wild type recombinant NMDA receptors.
A, Fluorescence images of HEK 293 cells expressing GluN2A and GluN2B containing NMDARs labeled with CypHer5E-conjugated BTX and BTX-AF488
treated with NMDA (50 μM) plus glycine (1μM) with or without glycine pre-treatment. Scale bar = 10 μm. B, Left Representative Western blot of co-
immunoprecipitation of NMDARs with adaptin β2 from cell lysate treated with glycine (100μM) plus APV (100μM) or APV (100μM) alone. Right
Quantification is summarized in the histogram showing mean GluN1-adaptin β2 association after glycine treatment (n = 10). Data are presented as
mean percent (± s.e.m.) of APV treated group. Data were normalized to the amount of adaptin β2 immunoprecipitated. ** indicates p < 0.01
*** indicates p < 0.001 compared to control.
Han et al. Molecular Brain 2013, 6:36 Page 4 of 14
http://www.molecularbrain.com/content/6/1/36the enhancement of GluN1 co-immunoprecipitation
with anti- adaptin β2 (Figure 3A). Additionally, applying
L689560 together with glycine (100 μM) prevented the
decrease in cell-surface NMDARs evoked by subsequent
treatment with NMDA (50 μM) plus glycine (1 μM)
(Figure 3B). The effects of L689560 to block the glycine-
enhanced AP-2-NMDAR association and the glycine-
stimulated reduction in cell-surface NMDARs were ob-
served with GluN1/GluN2A and with GluN1/GluN2Breceptors (Figure 3A and B). Thus, the effect of L689560
on recombinant NMDARs matched its effects on native
NMDARs in neurons [10].
Glycine-primed internalization of native NMDARs and
depression of neuronal NMDAR currents is prevented
by blocking dynamin dependent endocytosis [10]. We
therefore examined the effects of dynamin inhibitors on
glycine priming and internalization of recombinant


































































































Figure 3 Pharmacological blocker of the glycine binding site
prevents glycine primed NMDAR endocytosis. A, Top
Representative Western blot of co-immunoprecipitation of NMDARs
with adaptin β2 from HEK293 cells expressing recombinant wild
type NMDARs treated with ECS, glycine (100 μM) with or without
L689560 (1μM), or with L689560 alone. Bottom, Histograms showing
quantification of GluN1 and adaptin β2 association after glycine
stimulation with or without L689560 (n = 4). Data are normalized to
ECS group and presented as mean percent of ECS control (± s.e.m).
B, NMDAR internalization measured by cell ELISA assay. Cultures
(n = 5) were pre-treated with glycine (100 μM) plus APV (100 μM)
with or without L689560 (1μM) followed by NMDA (50 μM) plus
glycine (1μM). * indicates p <0.05, ** indicates p < 0.01 compared
to L689560-treated group.
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expressed together with recombinant NMDARs. We
found that expressing dynamin2-K44A prevented the
glycine-induced decrease of cell-surface levels of GluN1/
GluN2A and GluN1/GluN2B receptors (Figure 4A). By
contrast, expressing wild-type dynamin 2 had no effect on
the glycine-primed reduction of cell surface NMDARs.
Second, we intracellularly administered dynasore, a non-
competitive inhibitor of dynamin 1 and dynamin 2
[25,26], during whole cell recordings. We found that dur-
ing recordings with dynasore, currents evoked from
GluN1/GluN2A or GluN1/GluN2B receptors did not de-
cline after glycine treatment (Figure 4B). By contrast, in
vehicle-control cells glycine induced a progressive reduc-
tion in NMDA-evoked currents (Figure 4B).
Collectively, these results show that wild-type recombin-
ant NMDARs expressed in HEK293 cells are subject to
glycine-primed internalization that is dynamin-dependent.
Glycine primes internalization when the receptors are
comprised of either GluN1/GluN2A or GluN1/GluN2B
subunits. Thus, the characteristics of the glycine-primed
internalization of the recombinant receptors fully recap-
itulate those of glycine-primed internalization of native
NMDARs in neurons.
GluN1 mutant receptors that lack glycine priming
Having established that glycine-primed internalization
was recapitulated with recombinant NMDARs, we mu-
tated residues in the ligand-binding domain of GluN1 to
test the hypothesis that glycine priming depends upon
glycine binding to this subunit. We first used a GluN1
mutant carrying four amino acid substitutions, N710R,
Y711R, E712A, A714L, which impaired but did not abol-
ish gating of NMDARs containing this GluN1 mutation
[27,28]. We found that NMDARs with this quadruple
GluN1 mutation, which we refer to as the RRAL mutant,
were expressed at levels comparable to those of wild-
type GluN1 when co-transfected with GluN2B, but there
was no detectable expression if co-transfected with
GluN2A (data not shown). Therefore, we tested glycine
priming only with mutant GluN1/GluN2B receptors.
We investigated GluN1.RRAL /GluN2B using the four
approaches established for wild-type receptors. Consist-
ent with the reported reduction in potency of glycine
with RRAL mutant receptors [27,28], applying NMDA
(50 μM) and glycine (1 μM) evoked no currents with
GluN1.RRAL/GluN2B receptors (not illustrated). How-
ever, stimulating with test applications of NMDA (50 μM)
plus glycine (100 μM) evoked currents that were stable for
at least 40 min (Figure 5A), demonstrating that gating of
the mutant receptors is evoked by increasing glycine con-
centration in the test applications. It was conceivable that
the potency of glycine for priming NMDARs might not
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Figure 4 Glycine primed NMDAR internalization and depression of NMDAR mediated currents require dynamin. A, Co-expression of
mutant dynamin K44A (Dyn_K44A) but not wild-type dynamin blocks glycine primed depletion of surface NMDA receptors (n = 4). * p <0.05,
**p <0.01, paired t-test. B, Representative traces show responses to the test applications recorded from cells expressing GluN1/GluN2A that were
treated with vehicle (DMSO, upper) or treatment (Dynasore, lower). Glycine (100 μM) was applied for 5 min where indicated. In the expanded
traces on the right, time indicates time after glycine treatment. The graphs show normalized NMDA-evoked peak currents from recordings with
intracellular administration of vehicle or dynamin inhibitor dynasore (80 μM) before and after glycine conditioning (indicated by the bar above
each graph) for cells transfected with GluN1/GluN2A (n = 4 cells; left panel) or with GluN1/GluN2B (n = 6 cells; right panel).
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(100 μM) for 5 min and found that there was no subse-
quent change in the amplitude of the currents evoked by
the test applications (data not shown). Thus, the glycine
stimulation that primed reduction in current amplitude of
wild-type NMDARs had no effect on the GluN1.RRAL/
GluN2B mutant.Because glycine potency for NMDAR gating is reduced
in RRAL receptors [28], we examined the effect of treating
the mutant receptors with glycine at concentrations in
excess of that needed to compensate for the reduction
in gating potency. RRAL receptors show a 330-fold reduc-
tion in glycine potency for evoking NMDAR currents















































































































































Figure 5 Mutant GluN1.RAAL/GluN2B receptors did not show glycine priming. A, Left, Traces show individual responses to the test
applications recorded from cells expressing GluN1/GluN2B (upper) or GluN1.RRAL/GluN2B (lower). Times indicates time after glycine treatment (10 mM,
5 min); t = 0 is the first response after glycine treatment. Right, Normalized NMDA currents (I/I0) vs time from cells expressing GluN1/GluN2B (n = 4
cells) or GluN1.RRAL/GluN2B (n = 9 cells). Glycine (10 mM, 5 min) was applied during the period indicated by the bar above the graph. B, NMDAR
internalization as quantified by cell ELISA assay using HEK293 cells expressing GluN1/GluN2B or GluN1.RRAL/GluN2B receptors. Cultures (n = 6) were
pre-treated with ECS or ECS containing glycine (10mM) plus APV (100 μM) followed by ECS or with NMDA (50 μM) plus glycine (100 μM). * indicates
p < 0.05 compared with ECS control. C, Cells expressing BBS-GluN1.RRAL/GluN2B showed minimal CypHer5E fluorescence after treatment of NMDA
(50 μM) plus glycine (100 μM) with 10 mM glycine plus 100 μM APV pre-treatment. Scale bar = 10 μm. D, Top, Representative Western blot of co-
immunoprecipitation of NMDARs with adaptin β2 from cell lysate treated with glycine (10 mM) plus APV (100 μM) or APV (100 μM) alone. Bottom,
Quantification was summarized in the histogram showing mean GluN1-adaptin β2 association from HEK293 cells expressing GluN1/GluN2B and GluN1.
RRAL/GluN2B receptors after glycine treatment (n = 10). Data are presented as mean percent (± s.e.m.) of APV treated group. Data were normalized to
the amount of adaptin β2 immunoprecipitated. ** indicates p < 0.01 compared to control.
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NMDARs [10]. We found that mutant receptors exposed
to glycine at 10 mM showed no subsequent decline in cur-
rents evoked by test applications, rather the currents were
stable for up to 30 min (Figure 5A). To investigate
whether increasing glycine concentration might, paradox-
ically, prevent the decline in NMDAR currents with wild-
type receptors, we exposed cells expressing GluN1/
GluN2B to high glycine (10 mM). After this high glycine
treatment the amplitude of the test currents declined
NMDAR currents to approximately 50% of that before
glycine treatment (Figure 5A). Thus, we found no evi-
dence for glycine-primed reduction of NMDAR currents
of GluN1.RRAL/GluN2B receptors even when the glycine
concentration was increased to compensate for the reduc-
tion in gating potency for glycine.
We therefore investigated whether there was a corre-
sponding lack of glycine-primed internalization of the
RRAL mutant receptors. Using cell ELISA approach we
found that pretreating with glycine (10 mM) followed by
treatment with NMDA (50 μM) plus glycine (100 μM)
caused no change in cell-surface levels of the mutant
receptors (Figure 5B). By contrast, GluN1/GluN2B
cell-surface level was significantly decreased to 73 ± 3%
(p < 0.05) of ECS control. Moreover, we generated and
tested GluN1.RRAL/GluN2B mutant receptors tagged
with the BTX-binding sequence at the N-terminus. In
contrast to the robust receptor endocytosis observed
with wild-type BBS-tagged GluN1/GluN2B receptors,
glycine (10 mM) pre-treatment followed by treatment
with NMDA (50 μM) plus glycine (100 μM) produced
no detectable CypHer5E fluorescent signal in cells
expressing BBS-tagged GluN1.RRAL/GluN2B mutant
receptors (Figure 5C). However, there was robust cell-
surface expression of the mutant receptors as shown
by the BTX-AF488 fluorescence signal (Figure 5C).
Thus, we conclude from these findings that NMDARs
containing the RRAL GluN1 mutation fail to show
glycine-primed internalization.
To determine whether the lack of glycine-primed in-
ternalization of the mutant receptors may have been due
to lack of priming by glycine, as opposed to lack of in-
ternalization per se of primed receptors, we investigated
whether glycine stimulation recruits AP-2 to the mutant
receptors. Basal association of adaptin β2 with GluN1.
RRAL/GluN2B was comparable to that of wild-type
NMDARs. However, glycine (10 mM) did not alter the
amount of GluN1.RRAL that co-immunoprecipitated with
anti-adaptin β2 (Figure 5D). The association of wild-type
receptors with adaptin β2 significantly increased upon
treatment with glycine (10 mM) (Figure 5D). As glycine
does not enhance the association between AP-2 and
the mutant NMDARs we conclude that GluN1.RRAL/
GluN2B receptors lack glycine priming.GluN1 A714L mutation abolishes glycine priming
Of the four amino acid changes in the RRAL mutant,
only A714L impairs glycine potency as a single point
mutation [28]. Therefore, we investigated the effect of ala-
nine to leucine mutation at residue 714 (GluN1.A714L)
on glycine-primed internalization of NMDARs. GluN1.
A714L/GluN2B receptors formed functional NMDARs as
illustrated by the currents evoked by applying NMDA
(50 μM) plus glycine (100 μM; Figure 6A). We found
that treating GluN1.A714L/GluN2B receptors with
glycine, at concentrations up to 10 mM, had no effect
when investigated with any of the four approaches: i)
NMDA-evoked currents were stable after glycine (10 mM)
treatment (Figure 6A), ii) cell-surface GluN1.A714L/
GluN2B receptor levels did not change with glycine pre-
treatment (10 mM) followed by activation with NMDA
(50 μM) plus glycine (100 μM; Figure 6B), iii) GluN1.
A714L/GluN2B receptors did not internalize after
glycine pre-treatment (10 mM) followed by receptor
activation with NMDA (50 μM) plus glycine (100 μM;
Figure 6C), and iv) association of AP-2 with the
GluN1.A714L/GluN2B receptors did not change with
glycine (10 mM) treatment (Figure 6D).
Thus, the single mutation of alanine to leucine at 714
in GluN1 was sufficient to prevent all of the indicia of
glycine-primed internalization. The potency of glycine at
GluN1.A714L receptors has been shown to be reduced
only 62-fold compared with that of wild-type receptors
[28]. Thus, A714L mutation abolished glycine priming
even though glycine concentration was increased far
more than needed to compensate for the reduced glycine
potency for gating the GluN1.A714L mutant receptor.
Discussion
In this study we found that with wild-type NMDARs com-
prised of GluN1/GluN2A or GluN1/GluN2B: i) glycine
primed an approximate 50% reduction in NMDA-evoked
currents, ii) glycine pre-treatment induced a dramatic re-
duction in NMDAR cell-surface levels upon subsequent
NMDAR activation, iii) glycine pre-treatment, with subse-
quent NMDAR activation, provoked robust NMDAR in-
ternalization into an acidic intracellular compartment; iv)
glycine recruited AP-2 to the NMDAR complex. These ef-
fects of glycine were blocked by a glycine-site antagonist
or by disrupting dynamin function. Thus, like native
NMDARs, wild-type recombinant NMDARs undergo
homologous glycine-primed internalization that is dynamin-
dependent. The glycine priming process was observed with
NMDARs comprised of either GluN1/GluN2A or GluN1/
GluN2B and thus priming is not dependent upon which of
the two GluN2 subunits is partnered with GluN1.
In contrast to wild-type NMDARs, the mutant NMDARs
examined showed no signs of glycine priming or of













































































































































Figure 6 A714L mutation in GluN1 prevents glycine primed NMDAR internalization. A, Left, Traces show responses to the test applications
recorded from cells expressing GluN1/GluN2B (upper) or GluN1.A714L/GluN2B (lower). Times indicates time after glycine treatment (10 mM, 5
min); t = 0 is the first response after glycine treatment. Right, Normalized NMDA currents (I/I0) vs time of the experiment from cells expressing
GluN1/GluN2B (n = 4 cells) or GluN1.A714L/GluN2B (n = 3 cells) receptors. Glycine (10 mM, 5 min) was applied during the period indicated by the
bar above the graph. B, NMDAR internalization measured by cell ELISA assay using HEK293 cells expressing GluN1.A714L/GluN2B receptors (n = 6).
* indicates p < 0.05 compared to ECS control. C, Cells expressing BBS-GluN1.A714L/GluN2B showed no internalization as measured by CypHer5E
fluorescence in cells. Scale bar = 10 μm D, Top, Representative Western blot of co-immunoprecipitation of NMDARs with adaptin β2 from cell
lysate treated with glycine (10 mM) plus APV (100 μM) or APV (100 μM) alone. Bottom, Quantification is summarized in the histogram showing
mean GluN1-adaptin β2 association from HEK293 cells expressing GluN1/GluN2B and GluN1.A714L/GluN2B receptors after glycine treatment
(n = 10). Data are presented as mean percent (± s.e.m.) of APV treated group. Data were normalized to amount of adaptin β2 immunoprecipitated.
** indicates p < 0.01 compared to control.
Han et al. Molecular Brain 2013, 6:36 Page 9 of 14
http://www.molecularbrain.com/content/6/1/36
Han et al. Molecular Brain 2013, 6:36 Page 10 of 14
http://www.molecularbrain.com/content/6/1/36formed of GluN1.RRAL/GluN2B or of GluN1.A714L/
GluN2B: i) glycine application did not cause a change in
NMDA-evoked currents; ii) NMDAR cell-surface levels
were unchanged by glycine pre-treatment with subsequent
NMDAR activation; iii) glycine pre-treatment led to no
NMDAR internalization upon subsequent NMDAR activa-
tion; iv) AP-2 was not recruited to the NMDAR complex
by applying glycine. Both of the mutant GluN1 subunits
share conversion of alanine at position 714 to leucine, and
even the mutation of this residue alone prevented glycine
priming. Thus, our findings demonstrate that the single
amino acid in GluN1, A714, is critical for glycine priming
of NMDARs.
This critical residue at position 714 is within the
ligand-binding domain of GluN1 which is comprised of
two polypeptide segments, S1 and S2 [29]. The S1S2
segments form a bilobed structure. Crystallographic ana-
lysis of GluN1 S1S2 has revealed that, like other
ionotropic glutamate receptors, unliganded apo GluN1
is in an open conformation where S1 and S2 are apart,
like an open clamshell. Binding of glycine stabilizes a
closed conformation where S1 and S2 are in apposition
like a closed clamshell. This closed conformation of
S1S2 of GluN1, when occurring together with agonist
binding to the glutamate site in S1S2 of GluN2, induces
a cascade of conformational changes in the receptor
complex which ultimately leads to a conformational
state where the channel pore is open [30-37]. Lack of
glycine-induced recruitment of AP-2 in receptors carry-
ing the A714L mutation is strong evidence that S1S2 clos-
ure couples not only to channel pore opening but also to
additional conformational changes that allow AP-2 bind-
ing. As AP-2 binds to the intracellular region of the
NMDAR complexes, conformational changes induced
by S1S2 closure must be transduced across the cell
membrane [6].
A714 does not coordinate directly with bound glycine
[29], and therefore, reduction in glycine potency of
NMDARs containing the GluN1 A714L mutation may
be attributed to destabilization of the glycine-bound
closed conformation of GluN1 S1S2 causing inefficient
coupling to channel pore opening. The open conform-
ational state of the A714L mutant receptor complex is
nevertheless achieved as shown by the inward currents
evoked by applying NMDA plus glycine. But even at
concentrations far in excess of those needed to compen-
sate for changes in the potency for gating, glycine failed
to recruit AP-2 to the mutant NMDARs. This lack of
glycine-induced recruitment of AP-2 to the mutant re-
ceptor complexes demonstrates clear molecular dissoci-
ation of NMDAR priming from gating. The most
parsimonious explanation for these findings is that
destabilization of the closed S1S2 of GluN1 A714L,
which only partially reduces coupling to channelopening, eliminates coupling to the conformational
changes necessary for recruiting AP-2. If the NMDAR
complex cannot undergo the conformational changes
needed to recruit adapter proteins, as with the A714L
mutants, then the remaining endocytic machinery can-
not be assembled and endocytosis is prevented.
Recruitment of AP-2 induced by stimulating with gly-
cine is prevented by the glycine-site antagonist L689560
and, as well, L689560 alone did not cause AP-2 recruit-
ment. Binding of antagonists to S1S2 of ionotropic glu-
tamate receptors is believed to lead to a partially closed
state of the S1S2 which is unable to couple to gating
[29]. Our findings indicate that the conformation in-
duced by binding of glycine-site antagonists is not a con-
formation capable to recruit the core endocytic adaptor.
Moreover, binding of glutamate-site antagonists prevented,
and did not cause, NMDAR internalization indicating that
the remaining molecular machinery needed for endocytosis
was not subsequently assembled by antagonist-bound
NMDARs. In contrast, the non-competitive antagonist
MK-801 does not prevent glycine-primed internalization of
NMDARs (Nong et al., unpublished observation; see also
Vissel et al. 2001), indicating that ion flux through
NMDARs is not required for assembling the endocytic ma-
chinery. Blockade of priming and endocytosis of NMDARs
by glycine and glutamate site antagonists, respectively, con-
trasts with homologous internalization of AMPA receptors
where antagonists as well as agonists cause receptor in-
ternalization [38,39]. Thus, consequences of the conform-
ational changes induced by antagonist binding NMDARs
are distinct from those of AMPARs and there is no general
rule for effects of antagonists on homologous endocytosis
of ionotropic glutamate receptors.
The consequences of glycine-site occupancy reflect
differential coupling to two distinct effector outcomes –
channel pore opening or recruitment of endocytic adap-
tors. Coupling of agonist occupancy to multiple effectors
is well known for other cell-surface receptors such as
G-protein coupled receptors (GPCRs) [40]. For GPCRs, a
single type of receptor may couple to a large number of
distinct effectors, with the degree of coupling to specific
sets of effectors often determined by the ligand that acti-
vates the receptor [41]. Evidence from pharmacological
and structural studies indicates that GPCRs adopt mul-
tiple agonist-bound conformations which are able to re-
cruit different downstream binding partners and that
stabilization of different active conformations of the re-
ceptors engages distinct subsets of effectors [41,42]. Thus,
the conformational differences in NMDARs induced by
glycine that we infer lead to channel gating versus to
priming/endocytosis are analogous to the conformational
differences that underlie structure-biased effector coupling
with GPCRs. With GPCRs there is increasing structural
information about the intracellular regions of the
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[43]. We anticipate that such structural information about
NMDARs will ultimately provide the atomic level detail
needed to understand the channel gating and priming
effects of GluN1 binding of glycine.
Conclusions
In summary, we find that mutating alanine to leucine at
position 714 of GluN1, either alone or in tandem with
other point mutations, prevented glycine priming of
NMDARs. This critical amino acid is in the ligand-
binding region of GluN1, indicating that binding of gly-
cine to this NMDAR subunit is essential for priming the
receptors. Importantly, NMDARs with the A714L GluN1
mutation are functional channels when activated with the
co-agonists NMDA and glycine. Thus, our findings dem-
onstrate that the molecular determinants in GluN1 for
priming NMDARs by glycine are separable from those for
gating NMDARs by glycine acting as a co-agonist.
Methods
Molecular biology
Mammalian expression vectors encoding wild-type rat
GluN1-1a, GluN2A, and GluN2B cDNAs have been pre-
viously described [10]. The A714L mutation [28] and the
N710R Y711R E712A A714L (RRAL) mutations [27]
were introduced using the QuickChange site directed
mutagenesis kit (Stratagene, La Jolla, California). All
constructs were verified by DNA sequencing. Wild-type
and dominant-negative (K44A) mutant forms of dynamin2
were generously provided by S. E. Egan [24].
Cell culture and transfection
Human embryonic kidney cell line (HEK293) cells (3 × 104
cells/cm2) were plated onto 6-well culture dishes coated
with poly-D-lysine. HEK293 cells were cultured with
Dulbecco’s Modified Eagles Media (DMEM) (Invitrogen,
Burlington, ON, Canada) supplemented with 10% fetal bo-
vine serum (Invitrogen) and 1% penicillin-streptomycin
(Wisent, St. Bruno, QC) ); 37°C, 5% CO2. For electro-
physiological recordings in HEK293 cells, low density cul-
tures were plated 24 h before transfection on poly D-lysine-
coated glass coverslips. FuGene HD (Promega BioSci-
ences,LLC.: Sand Luis Obispo, CA, USA) transfections
always included GluN1-1a; a GluN2 construct, either 2A
or 2B; and PSD-95 at a DNA ratio of 1:4:0.5. For electro-
physiological recordings a plasmid containing enhanced
green fluorescent protein (eGFP) was also included in the
transfection at a ratio of 0.5 with respect to GluN1.
After transfection, cells were maintained in DMEM
supplemented with 10% fetal bovine serum and D-APV
(500 μM; Tocris, Minneapolis, MN, USA) for 48 hrs be-
fore experiments.Co-immunoprecipitation assay
HEK293 cells transfected with wild-type or mutant con-
structs were treated for 5 min with extracellular solution
(ECS) (pH 7.35, 330 mOsm; 140 mM NaCl, 1.3 mM
CaCl2, 5 mM KCl, 25 mM HEPES, 33 mM glucose)
supplemented with glycine site agonists and/or antago-
nists, or other reagents, as indicated. Cells were homog-
enized in ice cold lysis buffer (50 mM Tris–HCl (pH 8.0),
150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% NP-40, 0.5%
sodium deoxycholate, Complete Protease Inhibitor Cock-
tail Tablets (Roche, Indianapolis, IN, USA)). Insoluble ma-
terial was removed by centrifugation at 14,000 g for 20
min at 4°C. Cell lysates were incubated overnight with 2
mg of anti-AP-2 adaptin β2 (BD Biosciences). Immune
complexes were isolated by addition of 20 μl of mouse
protein G-Sepharose beads (GE Healthcare, Sweden),
followed by incubation for 1–2 h at 4°C. Immunoprecipi-
tates were then washed four times with lysis buffer,
resuspended in laemmli sample buffer, and boiled for 5
min. The proteins were separated by SDS–polyacrylamide
gel electrophoresis (PAGE), and transferred to a nitro-
cellulose membrane. Nitrocellulose membranes were
immunoblotted with anti-GluN1 or with anti-adaptin
β2 primary antibodies, and their respective secondary
antibodies conjugated to IR800 and IR700 (Rockland).
Antibody signals were quantified using the LICOR im-
aging system (LI-COR Biosciences, Lincoln, NE, USA).
Serial dilutions were used to confirm that under these
experimental conditions signal intensities for GluN1 or
adaptin β2 were linear over a 50-fold range. We note that
immunoprecipitating with a non-specific IgG caused no
detectable precipitation of GluN1 or adaptin β2.
Colorimetric cell enzyme-linked immunosorbent assay
(ELISA)
Assays were carried out as previously described [10].
Briefly, HEK293 cells transfected with wild-type or mu-
tant NMDARs were cultured in 12-well plates (approxi-
mately 2.5 × 105 cells per well). After removing the
media, HEK cells were covered in ECS and cooled to 4°C
to inhibit membrane trafficking. To pre-label cell surface
NMDA receptors, the cells were incubated for 1 hr at 4°C
with an anti-GluN1 antibody against the extracellular do-
main of GluN1 (BD biosciences; 2 μg ml-1). After treat-
ment with vehicle or ligands, HEK293 cells were fixed
with 4% paraformaldehyde in phosphate buffered sa-
line (PBS, Wisent) without detergents to prevent
permeabilization. After washing, cells were incubated
for 1 hr at room temperature with a horseradish peroxidase-
conjugated secondary antibody (1:1,000, Amersham). The
color reaction was produced by adding chromagenic sub-
strate (OPD; Sigma, St Louis, Missouri, USA) and stopped
with 0.2 volume of 3N HCl. The optical density of the
supernatant (1 ml) was read on a spectrophotometer at 492
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presented as a ratio of colorimetric readings measured on
cells not subject to the 15 min incubation at 37°C.Generation of α-bungarotoxin-binding-site tagged GluN1
A 13-aa α-bungarotoxin (BTX)-binding site (BBS) se-
quence [CTAGCTGGAGATACTACGAGAGCTCCCTG
GAGCCCTACCCTGACA (sense) and CTAGTGTCAG
GGTAGGGCTCCAGGGAGCTCTCGTAGTATCTCCAT
(antisense) [21]] was subcloned into a Hind III site intro-
duced downstream of the signal peptide in the GluN1-1a
subunit, referred herein as BBS-GluN1-1a, and subcloned
into pAEMXT-ACPwt (Covalys).CypHer5E mono NHS ester conjugation to BTX
CypHer5E N-hydroxysuccinimidyl ester (GE Healthcare,
Buckinghamshire, UK) was conjugated to unlabeled
BTX (Molecular Probes, Invitrogen) according to the
manufacturer’s instructions. Briefly, BTX was diluted to
1 mg/ml in PBS and 0.5 M sodium carbonate buffer, pH
8.3, and then incubated with 50-fold molar excess of
CypHer5E NHS for 1 hr at room temperature in the
dark. The CypHer5E-conjugated BTX (BTX-CypHer5E)
was separated from free CypHer5E by dialysis in PBS
overnight at room temperature. The molar concentra-
tion of antibody and dye in the final sample was then
calculated by measuring the absorbance of the labeled
BTX at 280 and 500 nm. The mean number of dye mol-
ecules coupled to the BTX was then determined. The
BTX-CypHer5E was diluted to 0.5 mg/mL with PBS
containing 0.1% BSA and stored frozen at −20°C.
Optical recording of internalization of NMDARs in live
cells using BTX-CypHer5E
We used CypHer5E, a pH-sensitive cyanine dye derivative,
excited at 633 nm and only fluorescent in acidic environ-
ments, to track agonist-induced NMDAR endocytosis.
Surface BBS-NMDARs were labeled with 3 μg/ml BTX-
CypHer5E at 4°C for 30 min, washed and pre-treated at
37°C with control ECS or 100 μM glycine for 5 min. The
labeling was sufficient to allow tracking of NMDARs with-
out saturating all the BBS-NMDARs. Live cells were then
treated with control ECS or NMDA (50 μM) plus glycine
(1 μM) for 10 min. After washing with cold ECS, cells
were incubated with Alexa Fluor®488-conjugated BTX
(BTX-AF488, Molecular Probes; 10 mM) at 18°C for 20
min. Cells were washed to remove unbound BTX-AF488
and then imaged using confocal microscopy (Olympus
IX81). Images were collected by a Hamamatsu Back-
Thinned EM-CCD camera using the Volocity software
(Perkin Elmer). Final processing was performed with
Adobe Photoshop CS5 without changing the original reso-
lution and color depth.Whole-cell recording
Whole-cell patch clamp recordings were generated from
HEK293 cells expressing recombinant wild-type or mu-
tant NMDARs together with GFP. Cells on cover slips
were transferred to a recording chamber and continually
perfused (approximately 1 ml min-1) in ECS (in mM):
NaCl, 140; KCl, 5.4; CaCl2, 1.3; Hepes, 25 and D-glucose,
33; Glycine, 0.001 (pH adjusted to 7.4 with NaOH). Cells
were visualized on an inverted microscope (Nikon)
equipped with epi-fluorescence and a GFP filter set. Patch
pipettes were made from borosilicate glass (World Preci-
sion Instruments) using a Brown-Flaming horizontal
puller (Model P-97, Sutter Instruments Co.) and were
fire-polished (MF-830 Microforge, Narishige). Micropi-
pettes had a resistance of 5–7 MΩ, formed gigaseals be-
tween 2 and 12 GΩ and were filled with intracellular
recording solution (in mM): CsF, 140; BAPTA, 10; Hepes,
10 and MgATP, 2 (pH adjusted to 7.2 with CsOH). Once a
gigaseal was formed, the cell was lifted up from the cover
slip to allow the ECS to flow to all surfaces of the cell. The
cell membrane potential was clamped at −60 mV.
NMDAR currents were evoked by test applications (3 s
duration) of NMDA (50 μM) and glycine (1 μM) at 60 sec
intervals with a SF-77B Perfusion Fast-Step system
(Warner Instruments). Applications of NMDA/glycine
were made for 5–10 min in order to establish a stable
NMDAR current baseline. Current traces were filtered at
2 kHz, digitized at 10 kHz and stored on a PC for later
analysis. Capacitive transients were minimized by analogue
means (in Figures, residual transients have been truncated
for illustrative purposes). Current amplitudes were mea-
sured at maximum inward peak for each NMDA applica-
tion. All analyses and voltage protocols were performed
using an Axopatch 1D amplifier in combination with a
Digidata 1200A interface and pCLAMP 9.0 software
(Molecular Devices). All recordings were made at
room temperature (20–22°C). NMDA-evoked current
data are presented as percentage of the peak mean
current (I) normalized to the initial response (I0). All
data are presented as means ± s.e.m. Where indicated,
the dynamin inhibitor, dynasore (80 μM) [25], was applied
through the patch pipette. Dynasore was dissolved in
DMSO, final DMSO concentration (0.2%). Once whole-
cell configuration was achieved, we allowed 10–15 min for
diffusion to the cell cytoplasm and then started recording
NMDA-evoked currents. Thus, dynasore was present be-
fore, during and after glycine priming. Control experi-
ments were performed in with DMSO alone (0.2%)
applied through the patch pipette.
Glycine priming protocol
For glycine priming experiments, we made a 5 min ap-
plication of glycine and D-APV (100 μM) with or with-
out glycine site antagonist L689560 (1 μM) [16,22,23] in
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But in experiments with mutant NMDARs glycine was
used, where indicated, at concentration of 10 mM. Note
that D-APV was included with all glycine priming treat-
ments in all types of experiment in order to avoid acti-
vating NMDAR channel gating. Afterwards, the glycine
priming solution was washed away for 1 min using con-
trol ECS, before re-probing NMDAR activity with the
test NMDA plus glycine applications every 60 s.
Statistical analysis
Statistical comparisons were made using Student’s t-test
or a non-parametric test (Mann–Whitney), as appropri-
ate; differences with p < 0.05 were considered statistically
significant. SigmaPlot v11.0 software was used for graph-
ical presentation. Results are presented as mean ± SEM.
Additional file
Additional file 1: Figure S1. Treatment of HEK293 cells with 100 mM
glycine for 5min did not change level of association between GluN1 and
Adaptin β2 protein.
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